Axsome Therapeutics, Inc. AXSM NASDAQ

Axsome Therapeutics, Inc. (AXSM) reported total assets of $689.81M and total liabilities of $601.51M for fiscal year 2025, resulting in total equity of $88.3M.

The company held $322.93M in cash and short-term investments. Total debt stood at $241.3M, with net debt of $-81.64M. The Debt-to-Equity (D/E) ratio was 2.73 (leveraged).

Current ratio is 1.55, indicating strong short-term liquidity. Interest coverage is -25.8x (weak).

Criteria supported by this page:

• HEALTH (33/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (70/100) — Total assets $689.81M and equity $88.3M support the company's competitive scale
• VALUE (90/100) — Debt-to-Equity 2.73 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

INCY

Incyte Corporation

$97.69

+2.24%

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

IMGN

ImmunoGen, Inc.

$31.24

+0.02%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

TGTX

TG Therapeutics, Inc.

$34.56

+2.28%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%